CMKLR1 and type 2 diabetes mellitus: CMKLR1 antagonists display a promising therapeutic effect in several animals disease models such as the myocardial infarction model (C15), type 2 diabetes model (CCX832), multiple sclerosis model (α-NETA), neuroblastoma xenograft model (α-NETA), and preeclampsia model (α-NETA) (Cash et al., 2013; Graham et al., 2014; Tümmler et al., 2017; Neves et al., 2018; Ji et al., 2021).